Skip to content
DataLookout
Menu

NCT07124351

Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)

StatusRecruiting
PhasePhase 4
Primary completion (estimated)

At risk: Primary completion moved at least 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Aug 2026 to Aug 31, 2027
    • Eligibility criteria expanded, about 11 words
    • Study completion pushed from Sep 2026 to Sep 30, 2027
  2. Notable Phase: Phase 1 to Phase 4
    • Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 2025 to Sep 5, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Feasibility of CYTALUX™ (pafolacianine) with near-infrared (NIR) fluorescent imaging
Timeframe: 12 months

Secondary (1)

Number of Lesions

Arms and interventions

CYTALUX™ (pafolacianine)Experimental

Enrolled subjects will be dosed with 0.025 mg/kg CYTALUX™ (pafolacianine) injection intravenously, with the hour-long infusion completing from 1 hour to up to 24 hours prior to imaging for the planned surgery.

Drugs: CYTALUX™ (pafolacianine)

Sites

1 site in 1 country

  • Cedars-Sinai Medical CenterLos Angeles, California, United States